Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | PRF1 | P14222 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 5/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29596271 | 0.89 | DDB1 (0.42) | ROCK1PRF1PRMT5WDR77LPL | |
| SCHEMBL2041419 | 0.89 | DDB1 (0.42) | ROCK1PRF1PRMT5WDR77LPL | |
| SCHEMBL2041556 | 0.86 | GRM5 (0.47) | ROCK1PRF1PRMT5WDR77LPL | |
| SCHEMBL29421580 | 0.86 | GRM5 (0.47) | ROCK1PRF1PRMT5WDR77LPL | |
| SCHEMBL28504213 | 0.84 | GRM5 (0.40) | ROCK1PRF1PRMT5WDR77LPL | |
| SCHEMBL22408571 | 0.83 | PRF1 (0.43) | ROCK1PRF1PRMT5WDR77LPL | |
| SCHEMBL7600541 | 0.82 | NPC1 (0.43) | ROCK1PRMT5WDR77LPLLIPG | |
| SCHEMBL15796223 | 0.82 | PRF1 (0.41) | ROCK1PRF1PRMT5WDR77LPL | |
| SCHEMBL15795865 | 0.82 | PRF1 (0.41) | ROCK1PRF1PRMT5WDR77LPL | |
| SCHEMBL30019043 | 0.81 | CA1 (0.38) | ROCK1PRMT5WDR77LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260069605-A1 | KRAS INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250250283-A1 | COMPOUND CAPABLE OF REGULATING AND CONTROLLING ACTIVITY OF 15-PGDH, AND PREPARATION METHOD THEREFOR | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-08-07 | — | — | US | disclosed |
| US-12304897-B2 | 15-PGDH inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| WO-2025080784-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | ROCK1 2186/4885PRF1 1760/4885PRMT5 1856/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | ROCK1 2186/4885PRF1 1760/4885PRMT5 1856/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | ROCK1 620/4885PRF1 4692/4885PRMT5 3441/4885 |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | ROCK1 609/4885PRF1 2649/4885PRMT5 1695/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | ROCK1 1150/4885PRF1 3216/4885PRMT5 939/4885 |
| US-12304897-B2 | 15-PGDH inhibitors | PTGIS, HPGD, PTGS1 | ROCK1 819/4885PRF1 1821/4885PRMT5 1119/4885 |
| US-20260069605-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | ROCK1 260/4885PRF1 2951/4885PRMT5 2258/4885 |
| US-20250250283-A1 | COMPOUND CAPABLE OF REGULATING AND CONTROLLING ACTIVITY OF 15-PGDH, AND PREPARATION METHOD THEREFOR | CYP11B1, CYP51A1, CYP11B2 | ROCK1 954/4885PRF1 2253/4885PRMT5 2292/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | ROCK1 2186/4885PRF1 1760/4885PRMT5 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.